FHTX: not every day when FDA puts partial clinical hold on a biotech's clinical trial following a patient's death and biotech finishes up >18%.
from Biospace article:
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome. This syndrome is commonly associated with AML and MDS treatments but remains deadly because leukemia cells release vast amounts of cytokines. Low blood pressure, breathing difficulties, fluid accumulation and fevers can present clinically. Differentiation syndrome is believed to be an on-target mechanism for FHD-286.
really interesting case where Foghorn's drug induces "differentiation" - causes an immature, leukemic progenitor myeloid cell to differentiate to a mature myeloid cell capable of producing a cytokines which creates a cytokine storm. This is why they describe differentiation syndrome as being "on-target" verification of MOA for FHD-286.
Cytokine storms are common side-effects of multiple therapies and diseases - Covid19. Typically, cytokine storms are treated with steroids to knock down the inflammation.